anti-VEGF treatment
PreclinicalSmall molecule
Bayeranti-VEGF treatment is one of 82 small molecule programs targeting Intelligence. It is currently in Preclinical.
5
Indications
5
Total Trials
2
Active Trials
81
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
39 competitors in Age-Related Macular Degeneration
#DrugCompanyPhaseTrials
1Eylea
RegeneronApproved
Zometa
PfizerApproved
Tecfidera
BiogenApproved
Bayer Aspirin
BayerApproved
Plavix
SanofiApproved
Visudyne
BBausch Health Americas, Inc.
Approved
Bendopa
MMerz North America, Inc.
Approved
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Lodosyn
LLaTonya J. Hickson
Approved
Acetadote
AArbor Pharmaceuticals, Inc.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Intelligence1 trial
Wet Age-Related Macular Degeneration1 trial
Dexamethasone1 trial
Age-Related Macular Degeneration1 trial
Effect of Micronutrient Supplementation on the Intestinal Microbiota in Patients With Age-related Macular Degeneration - The Gut-Retina-axis Study
Completed·—·N/A·NCT06391411·45 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for anti-VEGF treatment. EMBL-EBI & Wellcome Sanger Institute.
- [4]